Atenolol
DrugCrossover (atenolol 25-50 mg, bisoprolol 2.5-5 mg)
NCT Number: NCT01939509
At hemodynamic level, the greater affinity of bisoprolol by the beta 1 receptor in theory could improve the peripheral arterial perfusion and could have a greater antihypertensive effect. At the same time, this could carry objectifiable improvements in the vascular tree, such as the level of arterial stiffness.
This study attempts to mark the hemodynamic differences in the same individual with hypertension and metabolic syndrome who will be exposed to both drugs at different moments. Parameters will be objectified with impedance cardiography, pulse wave velocity and central blood pressure assessment before and after taking each one of the drugs. The results will be compared to the baseline data and between themselves.
Looking for future studies?
Notify Me21 year and older
All sexes
Interventional
Phase 4
Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Crossover (atenolol 25-50 mg, bisoprolol 2.5-5 mg)
Time frame: two months
Time frame: two months
Time frame: two months
Time frame: two months
Hospital Italiano de Buenos Aires
Other
Comparison of the Hemodynamic Changes in Patients Under Treatment With Bisoprolol Versus Atenolol
Acronym: CHAB
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06186102
Arterial Occlusive Diseases, Arteriosclerosis
Aarhus, Jutland, Denmark
View Trial DetailsNCT03326206
Cardiovascular Diseases, Chronic Disease
Chinle, Arizona, United States
View Trial DetailsNCT06460272
Body Weight, Cardiovascular Diseases
Cleveland, Ohio, United States
View Trial DetailsNCT04392284
Body Weight, Cardiovascular Diseases
Birmingham, Alabama, United States
View Trial Details